Biomarker-driven development of new therapies for autoimmune diseases: current status and future promises.
Laurence LaigleLoubna ChadliPhilippe MoingeonPublished in: Expert review of clinical immunology (2023)
The integration by AI-powered analytics of massive data provided by multi-omics technologies, high-resolution medical imaging and sensors borne by patients will eventually allow the identification of clinically relevant BMKs, likely in the form of combinatorial predictive algorithms, to support future drug development for autoimmune diseases.
Keyphrases
- high resolution
- end stage renal disease
- big data
- chronic kidney disease
- machine learning
- ejection fraction
- newly diagnosed
- healthcare
- artificial intelligence
- prognostic factors
- peritoneal dialysis
- deep learning
- mass spectrometry
- single cell
- current status
- patient reported outcomes
- tandem mass spectrometry
- liquid chromatography
- data analysis